The medication manufactured by Gilead Sciences contains 2 previously approved drugs (emtricitabine and tenofovir disoproxil fumarate) and 2 new drugs (elvitegravir and cobicistat). The drug’s common side effects include nausea and diarrhea, while severe side effects include new or worsening kidney problems, decreased bone mineral density, fat redistribution, and alternation in the immune system. A Boxed Warning states the drug cannot be used to treat chronic hepatitis B virus infection and warns of possible lactic acidosis and severe liver problems. Are you aware of other recent HIV/AIDS related actions taken by the FDA?

For more information, please visit the FDA

Advertisements